{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+nasal+spray+%28OC-01+Vehicle+Nasal+Spray%29",
    "query": {
      "intervention": "Placebo nasal spray (OC-01 Vehicle Nasal Spray)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T07:37:38.366Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03636061",
      "title": "Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OC-01 (varenicline) nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oyster Point Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2018-08-15",
      "completion_date": "2018-09-26",
      "has_results": true,
      "last_update_posted_date": "2021-10-25",
      "last_synced_at": "2026-10-09T07:37:38.366Z",
      "location_count": 3,
      "location_summary": "Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03636061"
    },
    {
      "nct_id": "NCT04036292",
      "title": "Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Disease (DED)"
      ],
      "interventions": [
        {
          "name": "OC-01 (varenicline) nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oyster Point Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 758,
      "start_date": "2019-07-23",
      "completion_date": "2021-02-05",
      "has_results": true,
      "last_update_posted_date": "2021-11-22",
      "last_synced_at": "2026-10-09T07:37:38.366Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Newport Beach, California • Fort Collins, Colorado + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04036292"
    },
    {
      "nct_id": "NCT05514041",
      "title": "Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "Varenicline solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo nasal spray (OC-01 Vehicle Nasal Spray)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stephenson Eye Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2022-10-11",
      "completion_date": "2023-12-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-09T07:37:38.366Z",
      "location_count": 1,
      "location_summary": "Venice, Florida",
      "locations": [
        {
          "city": "Venice",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05514041"
    },
    {
      "nct_id": "NCT05136924",
      "title": "IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vance Thompson Vision - MT",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2021-12-01",
      "completion_date": "2022-06-01",
      "has_results": false,
      "last_update_posted_date": "2021-11-30",
      "last_synced_at": "2026-10-09T07:37:38.366Z",
      "location_count": 1,
      "location_summary": "Bozeman, Montana",
      "locations": [
        {
          "city": "Bozeman",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05136924"
    },
    {
      "nct_id": "NCT05082974",
      "title": "Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OC-01 (varenicline 0.6mg/ml) nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vance Thompson Vision ND",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-10-20",
      "completion_date": "2022-08-03",
      "has_results": false,
      "last_update_posted_date": "2023-06-12",
      "last_synced_at": "2026-10-09T07:37:38.366Z",
      "location_count": 1,
      "location_summary": "West Fargo, North Dakota",
      "locations": [
        {
          "city": "West Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05082974"
    },
    {
      "nct_id": "NCT05161208",
      "title": "OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "OC-01 (varenicline 0.6mg/ml) Nasal Spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Center for Ophthalmic and Vision Research, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 75,
      "start_date": "2021-12-03",
      "completion_date": "2022-07-25",
      "has_results": false,
      "last_update_posted_date": "2022-11-03",
      "last_synced_at": "2026-10-09T07:37:38.366Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05161208"
    },
    {
      "nct_id": "NCT05045508",
      "title": "Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "OC-01 (varenicline 0.6mg/ml) nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) Nasal Spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brandon Baartman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2021-08-30",
      "completion_date": "2023-01-30",
      "has_results": false,
      "last_update_posted_date": "2021-09-22",
      "last_synced_at": "2026-10-09T07:37:38.366Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05045508"
    },
    {
      "nct_id": "NCT03688802",
      "title": "Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OC-01 (varenicline) nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle control) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oyster Point Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2018-09-25",
      "completion_date": "2019-09-30",
      "has_results": true,
      "last_update_posted_date": "2021-12-29",
      "last_synced_at": "2026-10-09T07:37:38.366Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03688802"
    },
    {
      "nct_id": "NCT03920215",
      "title": "Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Long Term Follow up Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OC-01 Low Dose, 0.12 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "OC-01 Mid Dose, 0.6 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "OC-01 High Dose, 1.2 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oyster Point Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2018-08-15",
      "completion_date": "2019-09-20",
      "has_results": true,
      "last_update_posted_date": "2023-11-01",
      "last_synced_at": "2026-10-09T07:37:38.366Z",
      "location_count": 3,
      "location_summary": "Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03920215"
    },
    {
      "nct_id": "NCT04957758",
      "title": "Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurotrophic Keratopathy"
      ],
      "interventions": [
        {
          "name": "OC-01 (varenicline) nasal spray 1.2 mg/ml",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oyster Point Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 113,
      "start_date": "2021-06-17",
      "completion_date": "2023-04-28",
      "has_results": true,
      "last_update_posted_date": "2024-05-07",
      "last_synced_at": "2026-10-09T07:37:38.366Z",
      "location_count": 31,
      "location_summary": "Dothan, Alabama • Irvine, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04957758"
    }
  ]
}